Am J Psychiatry 155:470-473, April 1998
© 1998 American Psychiatric Association
Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects
Thomas E. Schlaepfer, M.D.,
Eric C. Strain, M.D.,
Benjamin D. Greenberg, M.D.,
Kenzie L. Preston, Ph.D.,
Eric Lancaster, M.S.,
George E. Bigelow, Ph.D.,
Patrick E. Barta, M.D., and
Godfrey D. Pearlson, M.D.
OBJECTIVE: Humans experience the subjective effects of mu and kappa opioid agonists differently: mu agonists produce mainly euphoria, while kappa agonists are more likely to produce dysphoria. This study tested the hypothesis that these subjective effects would be associated with anatomically distinct changes in regional cerebral blood flow (CBF) relative to baseline as assessed with single photon emission computed tomography (SPECT). METHOD: Nine nondependent opioid abusers participated in the study. In the first phase of the study, the participants were acclimated to effects of the study drugs. In the second phase they underwent repeat challenges with the study drugs followed by an assessment of CBF with use of the SPECT tracer [99mTc]HMPAO. Medications tested were the prototypic mu agonist hydromorphone, the mixed agonist/antagonist butorphanol (which has a kappa agonist component of activity), and saline placebo. RESULTS: Subjective effects of the drugs were distinctly different. Hydromorphone produced increased ratings of "good effects," while butorphanol led to more "bad effects." Hydromorphone significantly increased regional CBF in the anterior cingulate cortex, both amygdalae, and the thalamus—all structures belonging to the limbic system. Butorphanol caused a less distinct picture of regional CBF increases, mainly in the area of both temporal lobes. CONCLUSIONS: This study demonstrates that opioids with different subjective effects also produce statistically significant patterns of change in regional CBF from baseline, and the regions of statistical significance appear in different brain regions. In addition, these results demonstrate the applicability of SPECT functional neuroimaging in the study of medications with potential abuse liability.
This article has been cited by other articles:
|
|
|
|
 
D. J. Scott, C. S. Stohler, C. M. Egnatuk, H. Wang, R. A. Koeppe, and J.-K. Zubieta
Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses
Arch Gen Psychiatry,
February 1, 2008;
65(2):
220 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Martin, R. A. Hurley, and K. H. Taber
Is Opiate Addiction Associated With Longstanding Neurobiological Changes?
J Neuropsychiatry Clin Neurosci,
August 1, 2007;
19(3):
242 - 248.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Becerra, K. Harter, R. G. Gonzalez, and D. Borsook
Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers.
Anesth. Analg.,
July 1, 2006;
103(1):
208 - 216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Benedetti, H. S. Mayberg, T. D. Wager, C. S. Stohler, and J.-K. Zubieta
Neurobiological Mechanisms of the Placebo Effect
J. Neurosci.,
November 9, 2005;
25(45):
10390 - 10402.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K. Tremblay, C. A. Naranjo, S. J. Graham, N. Herrmann, H. S. Mayberg, S. Hevenor, and U. E. Busto
Functional Neuroanatomical Substrates of Altered Reward Processing in Major Depressive Disorder Revealed by a Dopaminergic Probe
Arch Gen Psychiatry,
November 1, 2005;
62(11):
1228 - 1236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-K. Zubieta, J. A. Bueller, L. R. Jackson, D. J. Scott, Y. Xu, R. A. Koeppe, T. E. Nichols, and C. S. Stohler
Placebo Effects Mediated by Endogenous Opioid Activity on {micro}-Opioid Receptors
J. Neurosci.,
August 24, 2005;
25(34):
7754 - 7762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Volkow, G.-J. Wang, Y. Ma, J. S. Fowler, C. Wong, Y.-S. Ding, R. Hitzemann, J. M. Swanson, and P. Kalivas
Activation of Orbital and Medial Prefrontal Cortex by Methylphenidate in Cocaine-Addicted Subjects But Not in Controls: Relevance to Addiction
J. Neurosci.,
April 13, 2005;
25(15):
3932 - 3939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A R Lingford-Hughes, S J C Davies, S McIver, T M Williams, M R C Daglish, and D J Nutt
Addiction: Imaging in clinical neuroscience
Br. Med. Bull.,
March 1, 2003;
65(1):
209 - 222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. D'Souza, R. E. Harlan, and M. M. Garcia
Sexually dimorphic effects of morphine and MK-801: sex steroid-dependent and -independent mechanisms
J Appl Physiol,
February 1, 2002;
92(2):
493 - 503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Kiyatkin and R. A. Wise
Brain and Body Hyperthermia Associated with Heroin Self-Administration in Rats
J. Neurosci.,
February 1, 2002;
22(3):
1072 - 1080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Lewis, H. S. Mayberg, M. E. Fischer, J. Goldberg, S. Ashton, M. M. Graham, and D. Buchwald
Monozygotic Twins Discordant for Chronic Fatigue Syndrome: Regional Cerebral Blood Flow SPECT
Radiology,
June 1, 2001;
219(3):
766 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
